Drug intelligence / Profile preview

[18F]F-RESCA-3A12

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]F-RESCA-3A12 is a radiolabeled nanobody designed as an immunoPET imaging probe for the diagnosis of pancreatic cancer. It specifically targets Claudin 18.2 (CLDN18.2), a protein often overexpressed in certain cancers. Labeled with the positron-emitting isotope Fluorine-18, this agent allows for non-invasive visualization and quantification of CLDN18.2 expression in tumors via Positron Emission Tomography/Computed Tomography (PET/CT) scans, aiding in patient selection for targeted therapies and disease staging.

Targets

Claudin 18.2

Beyond the preview

Go deeper on [18F]F-RESCA-3A12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]F-RESCA-3A12.

Explore the full profile